Beisi Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Beisi Lin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Wen Xu
Department of Endocrinology and Metabolism The Third Affiliated Hospital of Sun Yat‐sen University, Guangdong Provincial Key Laboratory of Diabetology Guangzhou China
2 shared publications Bin Yao
Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publication- Daizhi Yang
Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-Sen University, Key Laboratory of Diabetology of Guangdong Province, Guangzhou 510630, China
1 shared publication Fen Xu
Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publication- Hua Liang
Department of Endocrinology and Metabolism The Eighth Affiliated Hospital Southern Medical University (The First People's Hospital of Shunde, Foshan) Foshan Guangdong China
1 shared publication - Longyi Zeng
Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8297
Effects of Intensive Insulin Therapy Within One Week on Glycemic Control and β-Cell Function in Patients with T2DM
Objective: To evaluate the impact of intensive insulin therapy (IIT) within 1 week on glycemic control and β-cell function indices in patients with type 2 diabetes mellitus (T2DM). Methods: This retrospective study included 726 patients with T2DM who underwent continuous subcutaneous insulin infusion within 1 week. Patients were divided into three groups based on disease duration: short (≤1 year), medium (>1 and p < 0.01 for both). HOMA-β, 30 min insulinogenic index, 30 min disposition index, and insulin secretion sensitivity index-2 markedly improved from baseline [37.69 (41.03) VS. 32.40 (46.06), 3.16 (3.97) VS. 2.12 (3.51), 336.85 (397.05) VS. 188.93 (263.45), and 185.92 (122.89) VS. 120.81 (90.12), respectively] (p < 0.01 for all). Insulin sensitivity, measured by HOMA-IR and Matsuda index, significantly improved (p < 0.01 for both). Significantly greater improvements in glycemic control and β-cell function measures were observed in patients with a shorter diabetes duration. Age, duration of diabetes, BMI, HbA1c, duration of IIT, and time in range were significantly associated with improvements in β-cell function indices. Conclusions: IIT within 1 week was associated with improved glycemic control and β-cell function indices in T2DM patients, with the most pronounced benefits observed in those with a shorter disease duration.
- 25 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8297
Open AccessEffects of Intensive Insulin Therapy Within One Week on Glycemic Control and β-Cell Function in Patients with T2DM
Objective: To evaluate the impact of intensive insulin therapy (IIT) within 1 week on glycemic control and β-cell function indices in patients with type 2 diabetes mellitus (T2DM). Methods: This retrospective study included 726 patients with T2DM who underwent continuous subcutaneous insulin infusion within 1 week. Patients were divided into three groups based on disease duration: short (≤1 year), medium (>1 and p < 0.01 for both). HOMA-β, 30 min insulinogenic index, 30 min disposition index, and insulin secretion sensitivity index-2 markedly improved from baseline [37.69 (41.03) VS. 32.40 (46.06), 3.16 (3.97) VS. 2.12 (3.51), 336.85 (397.05) VS. 188.93 (263.45), and 185.92 (122.89) VS. 120.81 (90.12), respectively] (p < 0.01 for all). Insulin sensitivity, measured by HOMA-IR and Matsuda index, significantly improved (p < 0.01 for both). Significantly greater improvements in glycemic control and β-cell function measures were observed in patients with a shorter diabetes duration. Age, duration of diabetes, BMI, HbA1c, duration of IIT, and time in range were significantly associated with improvements in β-cell function indices. Conclusions: IIT within 1 week was associated with improved glycemic control and β-cell function indices in T2DM patients, with the most pronounced benefits observed in those with a shorter disease duration.
- Open Access
- 30 October 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-20
GLP-1 receptor agonist protects glucose-stimulated insulin secretion in pancreatic β-cells against lipotoxicity via PPARδ/UCP2 pathway
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) enhance glucose-stimulated insulin secretion (GSIS). Peroxisome proliferator-activated receptor δ (PPARδ) plays an essential role in mitochondrial function and glucose homeostasis. This study investigated the role of PPARδ in the protective effects of GLP-1RAs on pancreatic β-cells against lipotoxicity. C57BL/6J mice fed a high-fat diet (HFD) for 12 weeks were treated with exenatide (Exe), GW501516 (GW, a PPARδ agonist), saline, or dimethyl sulfoxide (DM) for 8 weeks, followed by phenotypic assessments. In vitro, mouse pancreatic β-cells (NIT-1 cells) were exposed to palmitic acid (PA), PA + exendin-4 (Ex-4), PA + GW, PA + GSK0660 (GSK, a PPARδ antagonist), or PA + Ex-4 + GSK. Compared to HFD mice treated with saline or DM, Exe and GW administration reduced fasting blood glucose, enhanced insulin secretion function and glucose tolerance, and upregulated PPARδ expression. NIT-1 cells treated with PA + Ex-4 and PA + GW showed enhanced GSIS capacity, increased PPARδ expression, decreased UCP2 expression and ADP/ATP ratio, and improved mitochondrial DNA content and mitochondrial membrane potential compared with those treated with PA alone, whereas the opposite results were observed in the PA + GSK group. In the PA + Ex-4 + GSK group, GSK attenuated the effects of Ex-4. PPARδ-knockout (KO) cells treated with PA exhibited similar changes to those treated with PA + GSK, and Ex-4 did not reverse these alterations. Moreover, Ex-4 failed to reverse mitochondrial function or GSIS in pancreatic β-cells with UCP2 overexpression despite an increase in PPARδ expression. Thus, GLP-1RA Exe/Ex-4 preserved GSIS against lipotoxicity in pancreatic β-cells by modulating mitochondrial function through the PPARδ/UCP2 axis.
- 30 October 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-20
Open AccessGLP-1 receptor agonist protects glucose-stimulated insulin secretion in pancreatic β-cells against lipotoxicity via PPARδ/UCP2 pathway
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) enhance glucose-stimulated insulin secretion (GSIS). Peroxisome proliferator-activated receptor δ (PPARδ) plays an essential role in mitochondrial function and glucose homeostasis. This study investigated the role of PPARδ in the protective effects of GLP-1RAs on pancreatic β-cells against lipotoxicity. C57BL/6J mice fed a high-fat diet (HFD) for 12 weeks were treated with exenatide (Exe), GW501516 (GW, a PPARδ agonist), saline, or dimethyl sulfoxide (DM) for 8 weeks, followed by phenotypic assessments. In vitro, mouse pancreatic β-cells (NIT-1 cells) were exposed to palmitic acid (PA), PA + exendin-4 (Ex-4), PA + GW, PA + GSK0660 (GSK, a PPARδ antagonist), or PA + Ex-4 + GSK. Compared to HFD mice treated with saline or DM, Exe and GW administration reduced fasting blood glucose, enhanced insulin secretion function and glucose tolerance, and upregulated PPARδ expression. NIT-1 cells treated with PA + Ex-4 and PA + GW showed enhanced GSIS capacity, increased PPARδ expression, decreased UCP2 expression and ADP/ATP ratio, and improved mitochondrial DNA content and mitochondrial membrane potential compared with those treated with PA alone, whereas the opposite results were observed in the PA + GSK group. In the PA + Ex-4 + GSK group, GSK attenuated the effects of Ex-4. PPARδ-knockout (KO) cells treated with PA exhibited similar changes to those treated with PA + GSK, and Ex-4 did not reverse these alterations. Moreover, Ex-4 failed to reverse mitochondrial function or GSIS in pancreatic β-cells with UCP2 overexpression despite an increase in PPARδ expression. Thus, GLP-1RA Exe/Ex-4 preserved GSIS against lipotoxicity in pancreatic β-cells by modulating mitochondrial function through the PPARδ/UCP2 axis.